About Acid sphingomyelinase-like phosphodiesterase 3b
Acid sphingomyelinase-like phosphodiesterase 3b (SMPDL3B) is a protein
from Homo sapiens identified by UniProt accession
Q92485, 455 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Acid sphingomyelinase-like phosphodiesterase 3b |
| UniProt accession | Q92485 |
| Gene | SMPDL3B |
| Organism | Homo sapiens |
| Length | 455 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (79)
Diseases linked to this target (Open Targets).
- Moyamoya disease · score 0.12
- erythrocyte count · score 0.12
- Red cell distribution width · score 0.10
- red blood cell density measurement · score 0.08
- hepatocellular carcinoma · score 0.08
- acute myeloid leukemia · score 0.07
- diabetic nephropathy · score 0.07
- platelet count · score 0.05
- platelet crit · score 0.05
- leukocyte count · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92485-F1 | alphafold | PREDICTED | 92.71 | — |
Amino-acid sequence (455 residues)
MRLLAWLIFL ANWGGARAEP GKFWHIADLH LDPDYKVSKD PFQVCPSAGS QPVPDAGPWG DYLCDSPWAL INSSIYAMKE IEPEPDFILW TGDDTPHVPD EKLGEAAVLE IVERLTKLIR EVFPDTKVYA ALGNHDFHPK NQFPAGSNNI YNQIAELWKP WLSNESIALF KKGAFYCEKL PGPSGAGRIV VLNTNLYYTS NALTADMADP GQQFQWLEDV LTDASKAGDM VYIVGHVPPG FFEKTQNKAW FREGFNEKYL KVVRKHHRVI AGQFFGHHHT DSFRMLYDDA GVPISAMFIT PGVTPWKTTL PGVVNGANNP AIRVFEYDRA TLSLKDMVTY FMNLSQANAQ GTPRWELEYQ LTEAYGVPDA SAHSMHTVLD RIAGDQSTLQ RYYVYNSVSY SAGVCDEACS MQHVCAMRQV DIDAYTTCLY ASGTTPVPQL PLLLMALLGL CTLVL
Explore Acid sphingomyelinase-like phosphodiesterase 3b with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets